1 medical monitoring: viral load testing: 1 medical monitoring: viral load testing Viral load testing
2 medical monitoring: viral load testing: 2 Slide 1 Viral load The viral load test measures HIV in the blood As the amount of HIV in the blood rises, more CD4 cells are lost Viral load rises very high just before a person becomes sick due to HIV viral load testing: 1 Viral load What is viral load? Viral load refers to the amount (the number of copies) of HIV genetic material (RNA) circulating in the blood plasma (the fluid that carries blood cells). A viral load test is therefore a blood test. A viral load test indicates the number of copies of HIV RNA per millilitre of blood. Viral load test results can range from less than 50 copies to more than 1 million copies. Some experimental tests used in research can detect as little as 5 copies per millilitre.
3 medical monitoring: viral load testing: 3 Slide 2 Natural history of disease progression key to symbols viral load (level in blood) CD4 count (level in blood) set point below the limit of the test viral load testing: 2 Natural history of disease progression Viral load is an indicator of disease progression. It shows how much virus is available to damage the immune system, and it can therefore be used to predict speed with which CD4 cells will be lost. Viral load steadily increases over time if no ART is used. The higher the viral load, the more damage the virus can cause to the immune system, and the more CD4 cells may be lost as a result. The lower someone s viral load, the less likely they are to get sick in the near future.
4 medical monitoring: viral load testing: 4 Slide 3 Predictors of disease progression Imagine HIV is a train heading for Paris. The time the train will arrive depends on both the speed of the train (viral load), and the length of the track left before Paris (CD4 count). viral load testing: 3 Predictors of disease progression Imagine HIV is a train heading for Paris. The time the train will arrive depends on both the speed of the train (viral load), and the length of the track left before Paris (CD4 count).
5 medical monitoring: viral load testing: 5 Slide 4 Key facts about viral load (1) Viral load of 100,000 is high Viral load of 10,000 is low When viral load is high, the risk of HIV transmission is greater viral load testing: 4 Key facts about viral load A viral load greater than 100,000 is considered to be high. A viral load less than 10,000 is considered low. Most people follow a pattern of: high viral load and low CD4 count, or low viral load and high CD4 count, However, a minority of people have discordant results which do not to fit the overall pattern (for example, high CD4 and high viral load). People who become HIV-positive over 50 years of age usually have lower CD4 counts, higher viral loads, and greater risk of disease progression than younger people. The reasons for this are unknown, though it may be due to the presence of other diseases in older people. Viral load and transmission If there are high levels of virus in the blood, there are also likely to be high levels of virus in semen or vaginal fluid. Therefore, people with high viral loads are likely to be more infectious. People with undetectable blood levels of virus might also continue to be infectious; however, because viral load in blood, semen and vaginal fluid does not match exactly. Although the risk of mother-to-baby transmission is very low in women with undetectable viral load, transmission can still occur. Similarly, it is possible to pass HIV to a sexual partner through exposure to semen or vaginal fluid, despite having an undetectable viral load.
6 medical monitoring: viral load testing: 6 Slide 5 Key facts about viral load (2) Viral load may be lower in women, so important to pay attention to CD4 count Viral load provides additional information to CD4 count but CD4 most important laboratory measurement viral load testing: 5 Key facts about viral load Viral load in women HIV viral load stabilises at a lower level in women following seroconversion. Among men, a low viral load following seroconversion is associated with less risk of disease progression. This is not the case for women. Early research into viral load and disease progression looked mainly at male-only cohorts of gay men and haemophiliacs. It was assumed that there was no difference in the way disease progressed in men and women. However, more recent research shows that women s viral loads are significantly lower compared to men with the same CD4 count. The reason for the sex difference in viral load and disease progression risk is unknown. A number of theories have been suggested, including: superior immune response to viral infections in women due to hormonal factors, reduced viral production in women, or exposure to low amounts of HIV due to mode of transmission. Viral load provides additional information Viral load provides additional information in untreated people in itself it is not sufficiently predictive because measurements can change considerably from one test to another, especially if blood is not stored properly or the test is not sufficiently sensitive to the subtype of HIV. The level of viral load is likely to predict the speed at which the CD4 cell count will fall, when considered in combination with the CD4 cell count.
7 medical monitoring: viral load testing: 7 Slide 6 MACS study Multi Center AIDS Cohort Study (MACS) Viral Load CD4 Count Below Above 750 Below 1500 ** ** ** ,501-7,000 ** ** ,001-20,000 ** ,001-55, above 55, Percentage of people who develop AIDS within three years (assuming no treatment). Viral load levels relate to results using RT-PCR test method, such as Roche Amplicor test. ** Indicates lack of data viral load testing: 6 MACS study The US Multicenter AIDS Cohort study (MACS) is the largest study which has explored the relationship between viral load and the natural progression of HIV infection if HIV remains untreated. The study enrolled over 1,600 symptom-free HIV-positive patients between 1984 and Blood samples were taken and frozen when they joined the trial and at six monthly intervals. Ten years later, when viral load testing became available, researchers went back to these samples and measured the viral load, comparing each individual s test results with his medical history. In this way, the researchers were able to build a picture of how future risk of illness varies according to a range of viral load and CD4 levels. This is shown in the graph which accompanies this section. The MACS study found that two people with the same CD4 count but different viral loads, might have a very different prognosis. The person with the higher viral load would be more likely to progress to AIDS faster. For example, at a viral load above 55,000 copies and a CD4 count above 750, there was a 32.6% chance of disease progression within three years. At the same viral load level but with a CD4 count below 200, the risk was 85.5%. Conversely, at viral loads below 7,000 copies, there was a very low risk of developing symptomatic disease (less than 3.7% at any CD4 level). Information from this study is still used in treatment centres to help with decision-making about ART. However, the results represents general trends and they are not a rule book which can be applied to all people with HIV. It is also important to remember that the study looked at the risk of disease progression in untreated people, and its findings cannot be applied to people whose test results have been influenced by the use of ART. The graph shows the percentage of people who might be expected to develop AIDS within three years (assuming they took no anti-hiv treatment), based on given viral loads and CD4 levels. Viral load measurements are related to results using the RT-PCR testing method, such as the Roche Amplicor test.
8 medical monitoring: viral load testing: 8 Slide 7 Viral load testing during treatment (1) May be measured just before starting, to get baseline' measurement Viral load should be `undetectable` after six months of treatment Undetectable = virus levels below the limit of detection of test Undetectable does not mean no virus viral load testing: 7 Viral load testing during treatment Where the test is available, viral load may be tested immediately before treatment is started, to provide a baseline measurement. If viral load is undetectable after six months, this is a sign that treatment is successfully controlling virus activity. The normal limit of detection is 50 copies or 400 copies. A viral load test with a limit of detection of 50 copies is more sensitive. However undetectable viral load does not mean that virus activity has stopped. It means that the test cannot detect virus levels of les than 50 copies.
9 medical monitoring: viral load testing: 9 Slide 8 Viral load testing during treatment (2) If virus levels rise above limit of detection, treatment may be failing Small increase (not above 1,000 copies) may be a temporary blip due poor adherence or minor infection Test again If viral load continues to rise, treatment is failing viral load testing: 8 Viral load testing during treatment If viral load subsequently rises above the limit of detection, the viral load test should be carried out again, since viral load can sometimes rise and fall for no important reason. If the second result is below the limit of detection, treatment does not need to be switched. If viral load has risen again, it is best to switch treatment as quickly as possible in order to reduce the risk of developing drug resistance. A rising viral load will usually be the first warning that treatment is failing. The sooner that treatment can be changed, the smaller the risk that the patient will develop drug resistance. If the CD4 count falls during treatment, it may be useful to test viral load to check whether this fall is caused by the failure of treatment or not. Factors affecting viral load With viral load tests (and with CD4 tests) it is the trend of results over time that matters, rather than the results of a single test. A temporary rise in viral load can be caused by various factors, especially things that stimulate the immune system, such as vaccinations. In a person not receiving ARV treatment, an opportunistic infection will cause a temporary tenfold increase in viral load, which will fall again when the infection has been successfully treated. The viral load (and CD4 count) will be different at different times of the day. It should therefore be measured each time at a similar time of day. It is also possible that viral load changes throughout the menstrual cycle in women.
10 medical monitoring: viral load testing: 10 Natural variations Researchers have investigated viral load changes in people who are not receiving ART. They have found that when levels are low (under 30,000 copies per ml) results from two separate tests on the same sample of blood can differ by a factor of five. For example, one sample might give a value of 5,000 and another sample a value of 25,000. In people receiving ARV treatment, viral load may increase temporarily above the limits of detection of the test if a person has an infection, or misses a dose or two of medication immediately before the test. The viral load may return below the limits of detection of its own accord within a few days without the need to change to treatment. However, if the viral load continues to rise, this is a sign that treatment is failing, and it should be changed as soon as possible in order to reduce the risk of developing resistance.
11 medical monitoring: viral load testing: 11 Slide 9 Log scale 1.0 logs logs logs logs 316 viral load testing: 9 Log scale Log changes Viral load test results are often written in a form known as the logarithmic scale, or logs. The logarithmic scale is used because it is a useful way for researchers to present trial data which include a wide range of values, from very high ones to very low ones. A one log change is a ten-fold change. For example, with a baseline load of 10 copies, a ten-fold increase would mean that the viral load rises to 100 copies (a one log change), a 2 log increase (a hundred-fold change) would see the viral load rise to 1,000 copies, a 3 log increase (a thousand-fold change) would see the viral load rise to 10,000 copies. Log values can be computed with a calculator, but here are a few examples: 1.0 logs = logs = logs = logs = logs = 1, logs = 3, logs = 10, logs = 31, logs = 100, logs = 316,228
12 medical monitoring: viral load testing: 12 Slide 10 HIV sub-types and viral load testing Numerous sub-types, or families, of HIV Viral load tests developed to recognise sub-type B in Europe, N America Not as sensitive to other subtypes? HIV-2 in West Africa: some viral load tests do not recognise viral load testing: 10 HIV sub-types and viral load testing Globally, HIV has evolved over time into a number of sub-types, or virus families. People who were infected with HIV in North America and Europe usually have HIV-1 sub-type B. People with HIV from other parts of the world (the majority of infected people worldwide) carry other sub-types. This has caused problems in the past with monitoring viral loads and tests for drug resistance,. Kits developed for use in North American and European markets have not always been sensitive to HIV sub-types found in other parts of the world. Fortunately this problem is gradually being resolved, and people with non-b HIV-1 sub-types are more likely now to receive accurate blood test results. However, this problem might reappear when new tests are developed in the future. Tests for HIV-2, which occurs in West Africa, have not been commercially available until recently. Some are now able to detect all subtypes of both HIV-1 and HIV-2, but others are still limited in the ranges of subtypes which they can detect.
13 medical monitoring: viral load testing: 13 Slide 11 Types of viral load test kit Roche PCR Amplicor HIV-1 Monitor Lower Limit of Detection: 50 copies. Bayer bdna Versant 3.0 Lower Limit of Detection: 50 copies. Organon Technika Nuclisens Lower Limit of Detection: 40 copies. viral load testing: 11 Types of viral load test kit There are two main types of viral load test: those that employ molecular techniques and those that use viral culture. The commercially available tests are molecular techniques, and most of these use quantitative PCR, or branchedchain DNA. Each test works in a slightly different way, but all tests look for HIV s genetic material. Because the results for different types of test may not be strictly comparable, it is best to ensure that the same type of test kit is always used to measure a patient s viral load using the same type of test kit. It is important to remember, and to tell the patient, that when a viral load result is classified as undetectable, it only means that the viral load is below the limit of detection of the testing kit. It does not mean that there is no virus in the patient s blood; The Roche PCR test is called the Amplicor HIV-1 Monitor. This detects HIV sub-types B, C and D,.but there is some doubt about its ability to detect other sub-types There have been two versions of this kit: the standard kit, with a lower detection limit of 400 copies and an upper limit of 750,000 copies the ultrasensitive kit, with a lower detection limit of 50 copies and an upper limit of 100,000; this version is used to monitor people with HIV in well-resourced settings such as the UK. A branched-chain DNA (bdna) test is marketed by Bayer under the name Versant 3.0. This is an ultrasensitive kit with a lower limit of 50 copies, and an upper limit of 500,000 copies. It has been validated for accurate detection of viral load in people infected with all sub-types of HIV. The Versant 3.0 is cheaper and easier to carry out and there is some evidence that it is better at detecting very low levels of virus. The Organon Technika Nuclisens test has a lower detection limit of 40 copies. It has been suggested that this test is less sensitive than both the Roche and Bayer tests and that it is less accurate at measuring non-b sub-types.
14 medical monitoring: viral load testing: 14 Comparing results Results from the older, less sensitive viral load kits, such as the standard Amplicor HIV-1 Monitor (lower detection limit 400 copies) and the Quantiplex 2.0 (lower detection limit 500 copies), could not be compared. A reading on the Quantiplex 2.0 needs to be doubled to get a comparable reading on the Roche kit, or divided to convert in the opposite direction.
15 medical monitoring: viral load testing: 15 Slide 12 Disadvantages Still costly Requires well-equipped laboratory, reliable electricity supply Requires considerable training of lab staff Some tests may not capture virus subtypes common in Africa and Asia very accurately Blood samples must be refrigerated and spun to separate plasma Accuracy of test will fall quickly if any delays in refrigeration Secure and reliable transport of blood samples viral load testing: 12 Disadvantages Although the Clinton Foundation has negotiated a reduction in the cost of two viral load tests, the tests are still costly. They also require a well-equipped laboratory, reliable electricity supply and highly trained staff who can handle a high volume of samples. It is not worth establishing a viral load testing laboratory unless it will be well used. Some tests may not capture virus subtypes common in Africa and Asia very accurately, particularly at low viral load levels (which are precisely the levels at which the tests need to be accurate if their main use is for monitoring treatment). In clinics where viral load might be used, a number of conditions would need to be met before the current generation of tests could be used in resource-limited settings. Blood samples must be refrigerated soon after they are drawn. Accuracy of the viral load test will fall quickly if any delays in refrigeration occur, or if there are any irregularities in the way that the blood is treated between leaving the patient s body and being used in the test. Secure and reliable transport of blood samples is also essential, so that blood samples do not go missing or become subjected to high temperatures.
16 medical monitoring: viral load testing: 16 Slide 13 Alternatives to viral load Cheaper options now being explored: P24 antigen Reverse transcriptase Dried whole blood spots viral load testing: 13 Alternatives of viral loads Viral load tests - reducing the cost One approach, as with CD4 tests, is to make viral load tests more affordable, through developing new technologies. However, all PCR-based tests depend on a high level of skill and may remain expensive. The other approach is to look at alternative ways of measuring the amount of the virus activity in blood samples. p24 antigen as an alternative to viral load The p24 protein is the main HIV core protein. Infected cells make it in larger quantities than other HIV proteins and therefore it is the easiest to detect. However, wwhen antibodies appear in the blood, they mask the p24 and make it harder to detect. There is now a commercial test kit for p24, from PerkinElmer Life Sciences, based on using heat treatment to separate antibodies that would otherwise mask p24 in the blood of people with HIV. In principle, it is possible to measure the production of the p24 as an alternative to viral load. However, even though the results of p24 tests might be as consistent as, or even more consistent than, viral load tests; they are not measuring exactly the same thing. Clinical studies are required to find out which of the tests is more relevant when a person is receiving ART. The two main advantages of the p24 test are its lower cost and the fact that samples can survive longer transport times, in more difficult conditions, without affecting the reliability of the test. Research continues, in order to validate the test in populations with non-subtype-b viruses that are commonly found in Africa and Asia. Measuring reverse transcriptase activity ExaVir LOAD is a test system from Cavidi Tech (Sweden) that measures levels of reverse transcriptase, the enzyme that defines retroviruses including HIV-1 (Braun).This test can measure the number of retrovirus particles in blood plasma, providing a closer equivalent to viral load testing than p24. It is much cheaper than RNA viral load testing, costing $15 per test, which the company hopes to reduce to $10. The test works equally well for HIV-1, regardless of subtype, and for HIV-2, but it cannot distinguish between them.
17 medical monitoring: viral load testing: 17 The biggest limitation is that it has a lower limit of detection between 350 and 700 copies per mm3 (the company claims 2,000). It requires a large sample - 1ml of plasma - which is a potential problem when diagnosing HIV in newborn babies. It also requires an overnight incubation stage, which requires a well equipped laboratory, and the kit must be stored in a freezer before use. Viral load test by dried blood spot The Retina Rainbow test has been developed by Primagen, a Dutch company. It uses dried blood spots or dried breast milk spots. This system is very convenient and cheap, because it does not need any refrigeration, special storage or transportation. The test is able to detect all HIV-1 subtypes, although accuracy seems to be higher for HIV-1 subtype B.
18 medical monitoring: viral load testing: 18 Slide 15 Questions 1. What does the viral load test measure? 2. When does it provide the most useful information? 3. What is undetectable viral load? 4. Can HIV be transmitted by someone with undetectable viral load? 5. At what level of viral load is treatment likely to be failing? 6. What should be the response to possible treatment failure? viral load testing: 14 Questions 1. What does the viral load test measure? The amount of HIV in the blood. High levels of HIV show that CD4 cells are likely to be lost more quickly, increasing the risk of illness. 2. When does it provide the most useful information? When the CD4 cell count is falling rapidly, and once a person has begun antiretroviral treatment. 3. What is undetectable viral load? Undetectable viral load means that levels of HIV in the blood are too low for the test to detect I.e below copies. 4. Can HIV be transmitted by someone with undetectable viral load? Yes, most likely to happen if they have a sexually transmitted infection that will increase levels of HIV in the genital fluids and blood. 5. At what level of viral load is treatment likely to be failing? If viral load rises above the limits of detection of the test, especially if it rises above 500 1,000 copies 6. What should be the response to possible treatment failure? Test viral load again if it is below copies, if above, refer immediately for treatment change.
HIV & AIDS What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease. What does HIV stand for? Human Immunodeficiency Virus Where did HIV
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) email@example.com The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?
The State Hospital HIV / AIDS The red ribbon is the international symbol of HIV & AIDS awareness. What is HIV? HIV stands for Human Immunodeficiency Virus: H is for Human - This virus infects human beings.
What Is HIV? HIV/AIDS: General Information & Testing in the Emergency Department HIV is the common name for the Human Immunodeficiency Virus. HIV is a retrovirus. This means it can enter the body s own
Appendix 3 Exposure Incident Report Form January, 2015 Page 1 of 6 Please see the following pages for the Exposure Incident Report Form. Guidelines for the Management of Exposure to Blood and Body Fluids
Frequently Asked Questions (FAQs) Research Rationale 1. What does PrEP stand for? There is scientific evidence that antiretroviral (anti-hiv) medications may be able to play an important role in reducing
ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES AIDS Law Unit Legal Assistance Centre July, 2002 INTRODUCTION Although there is currently no cure for HIV/Aids, treatment has, however, been developed
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous
Measuring the HIV Reservoir BINGO Review Activity Objectives Describe the differences in current technologies available for measuring the HIV reservoir Discuss the risk and benefit of each technology Methods
TRANSFER OF HIV MONITORING TECHNOLOGIES INTO RESOURCE-POOR SETTINGS: MOVING THE FIELD FORWARD REPORT OF A FORUM FOR COLLABORATIVE HIV RESEARCH WORKSHOP FEBRUARY 26, 2005; WASHINGTON DC FORUM FOR COLLABORATIVE
Bloodborne Pathogens Exposure Policy and Procedures Employees of the State of South Dakota Department of Health Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management PEP Hotline 1-888-448-4911 DOH
Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* ABOUT THIS ACTIVITY Time: 60 minutes Objectives: By the end of this session, participants will be able to: Reviewed their knowledge of HIV/AIDS
Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral
Didactic Series Updated Post-Exposure Prophylaxis (PEP) Guidelines Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 ACCREDITATION STATEMENT: University of California, San Diego School of
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
Basic Presentation HIV/AIDS For Use by Students, Teachers and the Public Seeking Basic Information About HIV/AIDS Objectives- Define and understand the difference between HIV Infection and AIDS Describe
Offering Testing for Hepatitis B and C in Primary Care Presentation 3 January 2014 Quality Education for a Healthier Scotland 1 Learning Outcomes Participants will be able to:- Undertake a pre-test discussion
William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016 Advisory Committee on Immunization Practices (ACIP) The recommendations to be discussed are primarily those of the ACIP composed of 15
Publication Report HIV Therapy Key Clinical Indicator (KCI) Year ending 31 December 2010 Publication date 27 September 2011 A National Statistics Publication for Scotland Contents Contents... 1 About ISD...
HIV Laboratory Testing: a Resource for Health Professionals Table of Contents Overview... 2 Window Periods and HIV Testing...2 Current HIV Testing System at Provincial Public Health Reference Laboratory...3
HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE DISEASE 101 ONLINE CONFERENCE SARAH WENINGER, MPH VIRAL HEPATITIS.STD.HIV PREVENTION COORDINATOR DECEMBER 3, 2015 OBJECTIVES Describe the populations that should
Estimates of New HIV Infections in the United States Accurately tracking the HIV epidemic is essential to the nation s HIV prevention efforts. Yet monitoring trends in new HIV infections has historically
Diagnosis of HIV-1 Infection Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University Tests Used to Diagnose HIV-1 Infection HIV antibody (today s topic) HIV p24 antigen HIV DNA HIV
Section 1 HIV and AIDS Today What Are HIV and AIDS? Human immunodeficiency virus (HIV) is the virus that primarily affects cells of the immune system and that causes AIDS. Acquired immune deficiency syndrome
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
Australian Federation of AIDS Organisations PO Box 51 Newtown NSW 2042 www.afao.org.au July 2009 Information on adherence and hints to help manage your HIV medications HIV TREATMENT ADHERENCE What is adherence?
UNIVERSITY OF OTTAWA OCCUPATIONAL HEALTH, DISABILITY AND LEAVE SECTOR MEASURES TO MINIMIZE EXPOSURE TO BLOODBORNE PATHOGENS AND POST-EXPOSURE PROPHYLAXIS POLICY Prepared by the Occupational Health, Disability
Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers James Wilton Coordinator, Biomedical Science of HIV Prevention
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
Edvo-Kit #S-70 How Does a Doctor Test for AIDS? S-70 Experiment Objective: The Human Immunodefi ciency Virus (HIV) is an infectious agent that causes Acquired Immunodefi ciency Syndrome (AIDS) in humans.
Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
Managing Bloodborne Pathogens Exposures House Staff Orientation 2015 Phillip F. Bressoud, MD, FACP Associate Professor of Medicine and Executive Director Campus Health Services University of Louisville
Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date
Sexually Transmitted Diseases Chapter Fourteen 2013 McGraw-Hill Higher Education. All rights reserved. The Major Sexually Transmitted Diseases Also known as sexually transmitted infections The Major STDs
Module 7: The Role of the Nurse Module Objectives To describe the dynamic role of the nurse in the holistic care of a patient receiving ARV treatment To equip nurses with a sense of importance and belief
HIV Looking after your sexual health 2 HIV HIV stands for Human Immunodeficiency Virus. Once someone is infected with HIV the virus will remain in their body for the rest of their life. There is currently
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
Dengue Virus Serology Testing 40% of the world s population is at risk of dengue infection Focus Diagnostics has been a leader in the development of infectious disease immunology assays for more than 25
1. What is herpes? 2. How common is herpes? 3. Is there a cure for herpes? 4. What is oral herpes (cold sores)? 5. How is oral herpes spread? 6. What is genital herpes? 7. How is genital herpes spread?
Issues in Brief: viral hepatitis testing Association of Public Health Laboratories May Viral Hepatitis Testing 9 APHL survey report In order to characterize the role that the nation s public health laboratories
4. LABORATORY 4A. Types of Laboratory Tests Available and Specimens Required Three main types of laboratory tests are used for diagnosing CHIK: virus isolation, reverse transcriptase-polymerase chain reaction
Full-fledged work is in progress towards construction and cloning of codon optimized envelope with subsequent aims towards immunization of mice to study immune responses. 1 2 4 5 6 Figure 4.1: Gel picture
ELISA BIO 110 Lab 1 Immunity and Disease Introduction The principal role of the mammalian immune response is to contain infectious disease agents. This response is mediated by several cellular and molecular
Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity
Black italics are the narration or interviews as recorded on the film Blue are the slides and text in the film Green are the printed notes that will accompany the videos is for stopping the film to answer
Couples HIV Counseling and Testing Module Six will clarify the implications of discordance and will explain the Couples HIV Counseling and Testing (CHCT) procedure for counseling discordant couples, including:
Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice Dr Chris Ford GP & SMMGP Clinical Lead Kate Halliday Telford & Wrekin Shared Care Coordinator Aims Discuss:
Immunity Unit Test Z Name MB Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Which of the pathogens in Figure 31.1 cause disease by taking over healthy
Quantitative HBV DNA measurements and the management of infected health care workers A.A. van der Eijk Department of Virology, Erasmus MC, Rotterdam, the Netherlands Introduction Worldwide since 1970s,
Public Health Activities & Services Inventory Technical Notes COMMUNICABLE DISEASE CLINICAL SERVICES, SURVEILLANCE AND CONTROL In 2014, decision was made to adopt number of national public health activities
Validation of finger-prick Dried Blood Spot (DBS) for HIV viral load monitoring in a decentralised programme in Thyolo, Malawi Dr. Laura Trivino Duran ( MedCo, MSF Malawi ) June 2012 Why do we use Viral
Diagnosis of HIV Infection in children by Associate Professor Kulkanya Chokephaibulkit Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University. Topic To Be Discussed WHO Testing
Q and A for PARTNER Studies: Interim analysis results presented at CROI 2014 STATUS: Results embargoed until 4 March 2014, 18:30 Central European Time (CET). CROI presentation can be found at www.chip.dk
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
HIV/AIDS Care: The Diagnosis Code Series 2 Prepared By: Stacey L. Murphy, MPA, RHIA, CPC AHIMA Approved ICD-10-CM/ICD-10-CM Trainer Learning Outcomes Identify and explain the difference between ICD-9-CM
HIV/AIDS PAPER OUTLINE 0.Introduction -Definitions 1. AIDS as a stigma -Factors to the AIDS stigma 2. Transmission to HIV - The most common ways that people get HIV 3. Where you can not get AIDS 4. Conclusion
HIV surveillance in Northern Ireland 2014 Contents Page 1 Surveillance arrangements 3 2 Introduction and key points 4 3 Trend information 5 - New diagnoses Route of transmission Age and gender CD4 surveillance
Cervical cancer screening with the HPV test and the Pap test in women ages 30 and older When to get tested and how to make sense of your test results If you are 30 years or older and your Pap test is normal
Technical Brief on HIV Viral Load Technologies (June 2010) Foreword Viral load assays have been widely evaluated by research laboratories and the results of the evaluations published in scientific literature;
DON T GET OR GIVE THE FLU THIS YEAR THANK YOU Vaccination is the only protection. www.immunisation.ie BE SURE. BE SAFE. VACCINATE. FLU VACCINE 2013-2014 Healthcare workers prevent the spread of flu and
P a g e 1 Coding and Billing for HIV Services in Healthcare Facilities The Hawai i State Department of Health STD/AIDS Prevention Branch is pleased to provide you information on billing and reimbursement
HIV Surveillance Update Presentation to: CAPUS Metro Atlanta Testing and Linking Consortium (MATLC) Presented by: Deepali Rane, MPH and Jane Kelly, MD Georgia Department of Public Health Epidemiology Date:
Adhering to Your Treatment Regimen Healthy LivingWith HIV www.patientedu.org/hiv There have been many advances in HIV treatment over the past few decades. These have led to the emergence of effective drug
HIV Guidelines. New Strategies. Santiago Moreno Hospital Universitario Ramón y Cajal Madrid HIV Guidelines. New Strategies. Outline HIV Guidelines What is new? New strategies Treatment as Prevention HIV
Viral Safety of Plasma-Derived Products SLIDE 1 This presentation will cover viral validation studies for plasma-derived products. FDA requires that the manufacturing process for biopharmaceutical products
Surgical Technology Program Directions for Completing the Application 2013-2014 Thank you for applying to the Surgical Technician program at the Ossining Extension Center of Westchester Community College.
The Natural Progression of Hepatitis C The natural history of hepatitis C looks at the likely outcomes for people infected with the virus if there is no medical intervention. However, the process of trying
Cervical cancer is the second most common cancer among South African women *SA Statistics as per National Cancer Registry (NCR) 2007 What is cervical cancer? Cervical cancer is a type of cancer that occurs
Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human Immunodeficiency
143 Chapter 10 Human Immuno Deficiency Virus Infection Chapter 10 Human Immuno Deficiency Virus Infection...143 HIV infection...144 Clinical Features...146 Clinical Staging of HIV infection recommended
HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally
Office of Origin: Occupational Health Program I. PURPOSE To provide a sustainable, healthy and safe working environment for UCSF research laboratory staff, and animal research care staff and to prevent
The Biotechnology Education Company Blood-Based Cancer Diagnostics EDVO-Kit 141 Store entire experiment at room temperature. EXPERIMENT OBJECTIVE: The objective of this experiment is to learn and understand
Zika Virus Frequently Asked Questions for the General Public Version 1.12: 25/7/2016 What is Zika? Zika is a viral infection that usually causes a mild illness that typically lasts between 2 and 7 days.
Outpatient/Ambulatory Health Services Service Definition Outpatient/ambulatory medical care includes the provision of professional diagnostic and therapeutic services rendered by a physician, physician
Types of HIV test There are two basic categories of HIV test 4 th generation and 3 rd generation. Each individual test differs as to what it tests (whether antibodies and/or p24 antigens), how it tests
EPIDEMIOLOGY OF HEPATITIS B IN IRELAND Table of Contents Acknowledgements 3 Summary 4 Introduction 5 Case Definitions 6 Materials and Methods 7 Results 8 Discussion 11 References 12 Epidemiology of Hepatitis
FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system) Mirena does not protect against HIV infection (AIDS) and other sexually transmitted infections
What is PrEP, or Pre-Exposure Prevention? JULY 2011 What is PrEP? An HIV-negative person would use PrEP by taking certain HIV medicines daily (in either a pill or microbicide) to help him or her prevent
GCSE BITESIZE Examinations General Certificate of Secondary Education AQA SCIENCE A Unit Biology B1a AQA BIOLOGY Unit Biology B1a BLY1A (Human Biology) (Human Biology) FOUNDATION TIER Specimen Paper Time
HIV/AIDS Treatment Information Service 1 800 HIV 0440 HIV and Its Treatment What You Should Know 2nd edition HIV/AIDS TREATMENT INFORMATION SERVICE 2nd Edition HIV and Its Treatment: What You Should Know
Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.
TTT s : Test and Treat Tracking System on ResearchKit of HIV Carriers in Thailand Rachasak Somyanonthanakul 1, Prapaipan Plodgratoke 2 1 Department of Medical Informatics, College of Information and Communication
Central Sterile Processing Program Directions for Completing the Application Fall 2012 Ossining Extension Center, 22 Rockledge Avenue Ossining, New York 10562 Thank you for your interest in the Central
THIS IS AN OFFICIAL NH DHHS HEALTH ALERT Distributed by the NH Health Alert Network Health.Alert@nh.gov December 11, 2014; 1030 EST (10:30 AM EST) NH-HAN 20141211 Start of Norovirus Season in New Hampshire